Author:
Suder A.,Ang J.E.,Kyle F.,Harris D.,Rudman S.,Kristeleit R.,Solca F.,Uttenreuther-Fischer M.,Pemberton K.,Pelling K.,Schnell D.,de Bono J.,Spicer J.
Reference35 articles.
1. Epidermal growth factor receptor inhibition in lung cancer: status 2012;Hirsch;J Thorac Oncol,2013
2. HER2 therapy—an abundance of riches;Gradishar;N Engl J Med,2012
3. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models;Li;Oncogene,2008
4. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker;Solca;J Pharmacol Exp Ther,2012
5. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial;Miller;Lancet Oncol,2012
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献